SCHEMBL30389411

SCHEMBL30389411

CC(C)C[C@@H]1NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC1=O

nearest known ligand 0.54

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.49
ROR1 Q01973 1/20 0.49
GRB2 P62993 2/20 0.48
OPRM1 P35372 1/20 0.48
OPRD1 P41143 1/20 0.48
OPRK1 P41145 1/20 0.48
GRB7 Q14451 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21430287 0.85 HDAC3 (0.48)
SCHEMBL22928930 0.85 HDAC3 (0.48)
Cyclomontanin D SCHEMBL30139332 0.81 SLC6A3 (0.54) FLT1GRB2
SCHEMBL31061607 0.80 FLT1 (0.53) FLT1GRB2
SCHEMBL13573536 0.80 ITGB3 (0.51) GRB7
SCHEMBL1370316 0.80 CXCR4 (0.53)
SCHEMBL21664109 0.77 OPRM1 (0.49) OPRM1OPRD1OPRK1
SCHEMBL31197219 0.77 SOAT2 (0.53)
SCHEMBL31197218 0.77 SOAT2 (0.53)
SCHEMBL29412929 0.77 HDAC4 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250295800-A1 CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION SAPREME TECH BV (NL) 2025-09-25 US disclosed
EP-4452325-A1 CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION Sapreme Technologies B.V. (NL) 2024-10-30 EP disclosed
US-20230302140-A1 CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION SAPREME TECHNOLOGIES B.V. (NL) 2023-09-28 US disclosed
US-20230248844-A1 COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE SAPREME TECHNOLOGIES B.V. (NL) 2023-08-10 US disclosed
WO-2023121447-A1 CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION SAPREME TECHNOLOGIES B.V. (NL) 2023-06-29 WO disclosed
EP-4171646-A1 CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION Sapreme Technologies B.V. (NL) 2023-05-03 EP disclosed
EP-4171647-A2 COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE Sapreme Technologies B.V. (NL) 2023-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250295800-A1 CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION CYP46A1, HCCS, DHCR7 FLT1 2324/4885ROR1 1136/4885GRB2 2354/4885
US-20230248844-A1 COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE HCCS, HAVCR2, HMBS FLT1 1612/4885ROR1 1386/4885GRB2 1600/4885
US-20230302140-A1 CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION CYP46A1, HCCS, DHCR7 FLT1 2324/4885ROR1 1136/4885GRB2 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.